Holen Sie sich die Stockscreener-App
1.22
5.17%
0.06
Handel nachbörslich:
1.13
-0.09
-7.38%
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
Indaptus Therapeutics Announces Routine Board Member Resignation - TipRanks
Indaptus Therapeutics, Inc. Announces Resignation of Tim Ruan from Director, Effective September 2, 2026 - marketscreener.com
Indaptus Updates ATM Agreement to Expand Capital Flexibility - TipRanks
Indaptus Therapeutics Launches $100 Million ATM Equity Program With H.C. Wainwright - tradingview.com
Indaptus sets up $100M at-the-market stock program - Stock Titan
Indaptus Therapeutics Launches $100M ATM Offering at $1.14 Per Share (NASDAQ: INDP) - Kalkine Media
Indaptus Therapeutics, Inc. SEC Filing (Aug 26, 2026) - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Indaptus Therapeutics Stock Price Forecast. Should You Buy INDP? - StockInvest.us
Indaptus Therapeutics Inc (NASDAQ: INDP) Share Price, INDP Stock News, INDP Share Price & Updates - Kalkine
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1% - MarketBeat
Indaptus Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Indaptus Therapeutics Q2 EPS beats estimate as loss narrows - scanx.trade
Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot - TipRanks
Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary - TradingView
Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2 - Stock Titan
Indaptus Q2 Net Loss Narrows to $1.8 Million - Quiver Quantitative
Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise - Stock Titan
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics (INDP) Falls 14% to $1.02 — Biotech Micro-Cap Tests Critical SupportDescending Triangle - vinanet.vn
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indaptus Therapeutics (INDP) Q4 2025 Earnings: Wider-than-Expected Loss Amid No RevenueReturn On Equity - dars.gov.et
Indaptus Therapeutics (INDP) to Announce Earnings on Monday - MarketBeat
Qinglai Lu Net Worth (2026) - GuruFocus
Indaptus Therapeutics Inc (INDP) Stock News Today - TradingKey
Indaptus Therapeutics (INDP) Slides 10.4% — Approaches Key Support at $1.23Ichimoku Entry - vinanet.vn
Indaptus Therapeutics (INDP) Slides 10.4% as Clinical-Stage Biotech Faces Selling PressureIchimoku Kumo Twist - vinanet.vn
INDP Q4 2025 Earnings: Wider-Than-Expected Loss Sends Shares Down 20.88%EPS Surprise History - vinanet.vn
Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.610|Chg%:-0.160 - TradingKey
Indaptus Therapeutics Inc (INDP) Balance Sheet - TradingKey
Indaptus Therapeutics (INDP) Plunges 21% – Key Support Levels in FocusMFI Divergence - vinanet.vn
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Indaptus Therapeutics Inc (INDP) Cash Flow - TradingKey
Indaptus Therapeutics Market Sentiment - Benzinga España
Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.060|Chg%:-0.550 - TradingKey
Indaptus Therapeutics, Inc. Revenue Breakdown – NASDAQ:INDP - TradingView
Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey
TradingKey - TradingKey
INDP Q4 2025 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Steep Stock DeclineConsensus Beat Rate - vinanet.vn
Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INDP Q4 2025 Earnings: EPS Falls Short of Estimates, Stock Rises Amid Pipeline ProgressHigh Growth Earnings - vinanet.vn
Indaptus Therapeutics (INDP) Q3 2025 earnings summary - Quartr
Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting - trinidadexpress.com
Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentOperating Margin Analysis - vinanet.vn
Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan - Stock Titan
INDP Q4 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Navigates Clinical Development - vinanet.vn
Insider Traders Lose US$34k As Indaptus Therapeutics Drops - simplywall.st
INDP Q4 2025 Earnings: Wider-than-Expected Loss as Stock Declines Nearly 6%Revenue Estimate Trend - dars.gov.et
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q4 2025 Earnings: EPS Misses Expectations Amid Zero Revenue; Stock Declines 1.96%Cost Structure Review - po-news-eg.net
Indaptus Therapeutics (INDP) News Flow - Moomoo
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Surprise Score - dars.gov.et
Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com - Investing.com Australia
Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares - Stock Titan
Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake - Stock Titan
Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance - Stock Titan
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):